Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P).
暂无分享,去创建一个
F. Saad | D. Rathkopf | K. Fizazi | C. Ryan | T. Griffin | Matthew R. Smith | A. Molina | A. Londhe